 On Thursday, Allogene Therapeutics Inc. NASDAQ:ALLO shares plummeted by more than 37 in the after-hours session after the US Food and Drug Administration FDA put on hold the clinical trial for AlloCAR T. The stock had surged 1.7 during the regular trading hours. 